CUSIP: 19516R107
What is CUSIP 19516R107?
CUSIP 19516R107 identifies CLGN - Collplant Biotechnologies Ltd. - Ordinary Shares, par value NIS 1.50 per share (including Ordinary Shares represented by American Depositary Shares at a 1-to-1 ratio) in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Open recent reporting periods for CUSIP 19516R107:
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sagy Ami | 13% | 1,637,086 | Ami Sagy | 19 Nov 2025 | ||||
| Loewenbaum Lilian S. | 9.9% | 0% | 1,256,056 | 0% | George Walter Loewenbaum | 06 Nov 2025 |
As of 31 Dec 2025, 1 institutional investors reported holding 3,253 shares of Collplant Biotechnologies Ltd. - Ordinary Shares, par value NIS 1.50 per share (including Ordinary Shares represented by American Depositary Shares at a 1-to-1 ratio) (CLGN). This represents 0.03% of the company’s total 12,690,589 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 3,253 | $4,555 | $1.40 | 1 | |
| 2025 Q3 | 3,253 | $8,752 | -$3 | $2.69 | 1 |
| 2025 Q2 | 3,254 | $4,425 | $1.36 | 1 | |
| 2025 Q1 | 3,254 | $8,394 | +$3 | $2.58 | 1 |
| 2024 Q4 | 3,253 | $11,713 | $3.60 | 1 | |
| 2024 Q3 | 3,253 | $16,154 | -$5 | $4.97 | 1 |
| 2024 Q2 | 3,254 | $16,170 | -$4,095 | $4.97 | 1 |
| 2024 Q1 | 4,078 | $21,815 | +$21,435 | $5.35 | 1 |
| 2023 Q4 | 71 | $454 | -$54,256 | $6.39 | 1 |
| 2023 Q3 | 8,556 | $47,657 | -$5,893 | $5.57 | 1 |
| 2023 Q2 | 9,614 | $78,450 | $8.16 | 1 | |
| 2023 Q1 | 9,614 | $67,490 | -$21,235 | $7.02 | 1 |
| 2022 Q4 | 12,639 | $105,536 | -$31,254 | $8.35 | 1 |
| 2022 Q3 | 16,382 | $111,000 | $6.78 | 1 | |
| 2022 Q2 | 16,382 | $131,000 | $8.00 | 1 | |
| 2022 Q1 | 16,382 | $192,000 | -$43,177 | $11.72 | 1 |
| 2021 Q4 | 20,066 | $328,000 | -$20,073 | $16.35 | 1 |
| 2021 Q3 | 21,294 | $360,000 | -$11,329,705 | $16.91 | 1 |
| 2021 Q2 | 552,029 | $11,708,000 | -$16,963,421 | $21.19 | 2 |
| 2021 Q1 | 1,813,871 | $24,376,000 | +$11,638,720 | $13.44 | 15 |
| 2020 Q4 | 950,357 | $10,232,000 | +$677,240 | $10.76 | 6 |
| 2020 Q3 | 890,518 | $7,422,000 | +$2,177,992 | $8.34 | 7 |
| 2020 Q2 | 628,916 | $6,282,000 | +$4,662,790 | $9.99 | 6 |
| 2020 Q1 | 162,398 | $1,495,000 | +$1,494,000 | $9.29 | 3 |
| 2019 Q4 | 106 | $1,000 | -$20,000 | $9.43 | 1 |
| 2019 Q3 | 5,304 | $21,000 | -$30,059 | $3.96 | 1 |
| 2019 Q2 | 12,902 | $52,000 | +$52,000 | $4.22 | 2 |